Back
Puma Biotechnology Quote, Financials, Valuation and Earnings
Unlock the Secret to Earning Monthly Income!
Limited spots act swiftly
Buy
52
PBYI
Puma Biotechnology
Last Price:
4.84
Seasonality Move:
31.31%
7 Day Trial
ALL ACCESS PASS
$
7
20 Most Hated Stocks on Wall Street
Click here to see the full list and protect yourself before it's too late.Puma Biotechnology Price Quote
$4.84
+0.09 (+2%)
(Updated: May 8, 2024 at 6:55 PM ET)
Puma Biotechnology Key Stats
Buy
52
Puma Biotechnology (PBYI)
is a Buy
Day range:
$4.58 - $4.78
52-week range:
$2.13 - $7.73
Dividend yield:
0%
P/E ratio:
10.54
P/S ratio:
1.00
P/B ratio:
4.49%
Volume:
321.7K
Avg. volume:
327.7K
1-year change:
50.63%
Market cap:
$228.9M
Revenue:
$235.6M
EPS:
$0.32
How Much Does Puma Biotechnology Make?
-
How Much Are Puma Biotechnology's Sales Annually?
PBYI Revenues are $235.6M -
How Much Profit Does Puma Biotechnology's Make A Year?
PBYI net income is $21.6M
Is Puma Biotechnology Growing As A Company?
-
What Is Puma Biotechnology's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.17% -
What Is Puma Biotechnology's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Puma Biotechnology Stock Price Performance
-
Did Puma Biotechnology Stock Go Up Last Month?
Puma Biotechnology share price went down by -16.17% last month -
Did PBYI's Share Price Rise Over The Last Year?
PBYI share price rose by 50.63% over the past 1 year
What Is Puma Biotechnology 52-Week High & Low?
-
What Is Puma Biotechnology’s 52-Week High Share Price?
Puma Biotechnology has traded as high as $7.73 over the past 52 weeks -
What Is Puma Biotechnology’s 52-Week Low Share Price?
Puma Biotechnology has traded as low as $2.13 over the past 52 weeks
Puma Biotechnology Price To Free Cash Flow
-
Is Puma Biotechnology Stock Overvalued?
Puma Biotechnology is trading at a price to free cash flow ratio of 6.37 -
Is Puma Biotechnology Stock Undervalued?
Puma Biotechnology EV to Free Cash Flow ratio is 6.23 -
What Is Puma Biotechnology’s Price Earnings Growth Ratio?
PBYI PEG ratio is 0.08 -
Is Puma Biotechnology Trading At A Premium To Earnings?
Puma Biotechnology EV to EBIT ratio is 7.41
Is It Risky To Buy Puma Biotechnology?
-
How Much Debt Does Puma Biotechnology Have?
Total long term debt quarterly is $100M -
How Much Cash Does Puma Biotechnology Have?
Cash and short term investments quarterly total is $107.2M -
What Is Puma Biotechnology’s Book Value Per Share?
Book value per share is 1.06
Is Puma Biotechnology Cash Flow Positive?
-
What Is PBYI Cash Flow From Operations?
Cash flow from operations (TTM) is $35.6M -
What Is Puma Biotechnology’s Cash Flow From Financing?
Cash flow from financing (TTM) is $0 -
What Is Puma Biotechnology’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$20.8M
Puma Biotechnology Return On Invested Capital
-
Is Management Doing A Good Job?
PBYI return on invested capital is 11.05% -
What Is Puma Biotechnology Return On Assets?
ROA measures how assets are converting to revenues and is 7.36% -
What Is PBYI Return On Equity?
ROE is a measure of profitability and is 38.55%
Puma Biotechnology Earnings Date & Stock Price
-
What Is Puma Biotechnology's Stock Price Today?
A single share of PBYI can be purchased today for 4.75 -
What Is Puma Biotechnology’s Stock Symbol?
Puma Biotechnology trades on the nasdaq under the ticker symbol: PBYI -
When Is Puma Biotechnology’s Next Earnings Date?
The next quarterly earnings date for Puma Biotechnology is scheduled on August 2, 2024 -
When Is PBYI's next ex-dividend date?
Puma Biotechnology's next ex-dividend date is May 9, 2024 -
How To Buy Puma Biotechnology Stock?
You can buy Puma Biotechnology shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Puma Biotechnology Competitors
-
Who Are Puma Biotechnology's Competitors?
Below is a list of companies who compete with Puma Biotechnology or are related in some way:
Puma Biotechnology Dividend Yield
Data Unavailable
Puma Biotechnology Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 67.74% |
| Revenue: | -17.07% | -10.77% |
Analyst Recommendations
| Buy Recommendations: | 0 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 0 |
| Price Target: | 4.33 |
| Downside from Last Price: | -8.68% |